Bristlecone Advisors LLC Sells 220 Shares of SPDR S&P Biotech ETF (NYSEARCA:XBI)

Bristlecone Advisors LLC trimmed its position in SPDR S&P Biotech ETF (NYSEARCA:XBI) by 1.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 19,953 shares of the exchange traded fund’s stock after selling 220 shares during the quarter. Bristlecone Advisors LLC’s holdings in SPDR S&P Biotech ETF were worth $1,971,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Affinity Asset Advisors LLC lifted its stake in shares of SPDR S&P Biotech ETF by 105.4% in the 2nd quarter. Affinity Asset Advisors LLC now owns 37,550 shares of the exchange traded fund’s stock valued at $3,481,000 after purchasing an additional 737,550 shares during the period. Healthcare of Ontario Pension Plan Trust Fund lifted its stake in SPDR S&P Biotech ETF by 30.3% in the first quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 3,136,000 shares of the exchange traded fund’s stock valued at $297,575,000 after buying an additional 730,000 shares during the period. Mirae Asset Securities USA Inc. bought a new position in SPDR S&P Biotech ETF during the second quarter worth about $55,626,000. Jane Street Group LLC grew its position in shares of SPDR S&P Biotech ETF by 68.7% during the 1st quarter. Jane Street Group LLC now owns 961,082 shares of the exchange traded fund’s stock worth $91,197,000 after buying an additional 391,333 shares during the period. Finally, Baymount Management LP acquired a new position in shares of SPDR S&P Biotech ETF during the 1st quarter worth about $34,160,000.

SPDR S&P Biotech ETF Price Performance

Shares of NYSEARCA:XBI opened at $97.15 on Friday. The firm’s 50 day simple moving average is $99.14 and its 200 day simple moving average is $94.62. SPDR S&P Biotech ETF has a fifty-two week low of $63.80 and a fifty-two week high of $103.52. The company has a market capitalization of $7.40 billion, a price-to-earnings ratio of 11.47 and a beta of 1.11.

About SPDR S&P Biotech ETF

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.